The registry of the international society for heart and lung transplantation: Thirtieth official adult heart transplant report - 2013; Focus theme: Age
TL;DR: This 30th adult heart transplant report is based on data submitted on 110,486 heart transplants in recipients of all ages by 407 centers worldwide since 1982 through June 30, 2012, with follow-up until June 30- 2012.
Abstract: This 30th adult heart transplant report is based on data submitted on 110,486 heart transplants in recipients of all ages (including 99,008 adults) by 407 centers worldwide since 1982 through June 30, 2012, with follow-up until June 30, 2012. Summary data are provided for the entire cohort of patients, whereas a number of additional analyses focus on cohorts who received transplants more recently. Detailed data analyses can be viewed in the International Society for Heart and Lung Transplantation (ISHLT) Registry slide sets available online (www.ishlt.org/registries). The report is divided into several sections:
Citations
More filters
TL;DR: Authors/Task Force Members: Piotr Ponikowski* (Chairperson) (Poland), Adriaan A. Voors* (Co-Chair person) (The Netherlands), Stefan D. Anker (Germany), Héctor Bueno (Spain), John G. F. Cleland (UK), Andrew J. S. Coats (UK)
13,400 citations
3,645 citations
30 Dec 2012
1,248 citations
TL;DR: The epidemiology, pathophysiology, causes, and outcomes of cardiogenic shock are summarized; contemporary best medical, surgical, mechanical circulatory support, and palliative care practices are reviewed; the development of regionalized systems of care is advocated; and future research priorities are outlined.
Abstract: Cardiogenic shock is a high-acuity, potentially complex, and hemodynamically diverse state of end-organ hypoperfusion that is frequently associated with multisystem organ failure. Despite improving survival in recent years, patient morbidity and mortality remain high, and there are few evidence-based therapeutic interventions known to clearly improve patient outcomes. This scientific statement on cardiogenic shock summarizes the epidemiology, pathophysiology, causes, and outcomes of cardiogenic shock; reviews contemporary best medical, surgical, mechanical circulatory support, and palliative care practices; advocates for the development of regionalized systems of care; and outlines future research priorities.
1,019 citations
TL;DR: The ISHLT Infectious Diseases, Pediatric and Heart Failure and Transplantation Councils Councils, and on behalf of the International Society for Heart Lung Trans transplantation (ISHLT) Infectious diseases, pediatric and heart failure and transplantation councilss are represented.
Abstract: Mandeep R. Mehra, MD (Chair), Charles E. Canter, MD, Margaret M. Hannan, MD, Marc J. Semigran, MD, Patricia A. Uber, PharmD, David A. Baran, MD, Lara Danziger-Isakov, MD, MPH, James K. Kirklin, MD, Richard Kirk, MD, Sudhir S. Kushwaha, MD, Lars H. Lund, MD, PhD, Luciano Potena, MD, PhD, Heather J. Ross, MD, David O. Taylor, MD, Erik A.M. Verschuuren, MD, PhD, Andreas Zuckermann, MD and on behalf of the International Society for Heart Lung Transplantation (ISHLT) Infectious Diseases, Pediatric and Heart Failure and Transplantation Councils
1,009 citations
Cites background from "The registry of the international s..."
...Heart retransplantation remains a small portion of overall adult transplants performed, accounting for approximately 3% of all transplants.(30) Although outcomes have improved in recent eras,(30) retransplantation remains in the highest 1-year mortality group and is also a significant predictor of long-term mortality....
[...]
...8% of HT recipients have an elevated panel-reactive antibody (PRA) test defined as 4 10%.(30) Published reports consistently support the association of elevations in circulating antibodies with an increase in mortality, rejection, and the development of cardiac allograft vasculopathy (CAV) in the post-transplant period, as well as longer waiting times and risk of mortality in the pretransplant phase....
[...]
References
More filters
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Abstract: In lifetesting, medical follow-up, and other fields the observation of the time of occurrence of the event of interest (called a death) may be prevented for some of the items of the sample by the previous occurrence of some other event (called a loss). Losses may be either accidental or controlled, the latter resulting from a decision to terminate certain observations. In either case it is usually assumed in this paper that the lifetime (age at death) is independent of the potential loss time; in practice this assumption deserves careful scrutiny. Despite the resulting incompleteness of the data, it is desired to estimate the proportion P(t) of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t). The observation for each item of a suitable initial event, marking the beginning of its lifetime, is presupposed. For random samples of size N the product-limit (PL) estimate can be defined as follows: L...
52,450 citations
Book•
01 Jan 1984
TL;DR: In this article, the authors give a concise account of the analysis of survival data, focusing on new theory on the relationship between survival factors and identified explanatory variables and conclude with bibliographic notes and further results that can be used for student exercises.
Abstract: The objective of this book is to give a concise account of the analysis of survival data. The book is intended both for the applied statistician and for a wider statistical audience wanting an introduction to this field. Particular attention is paid to new theory on the relationship between survival factors and identified explanatory variables. Each chapter concludes with bibliographic notes and outline statements of further results that can be used for student exercises. (ANNOTATION)
6,299 citations
01 Jan 2006
TL;DR: Regression models are frequently used to develop diagnostic, prognostic, and health resource utilization models in clinical, health services, outcomes, pharmacoeconomic, and epidemiologic research, and in a multitude of non-health-related areas.
Abstract: Regression models are frequently used to develop diagnostic, prognostic, and health resource utilization models in clinical, health services, outcomes, pharmacoeconomic, and epidemiologic research, and in a multitude of non-health-related areas. Regression models are also used to adjust for patient heterogeneity in randomized clinical trials, to obtain tests that are more powerful and valid than unadjusted treatment comparisons.
4,211 citations
TL;DR: The basic Bayesian framework must be constrained, use of the step function in computing the probability that a team would rank best or worst in a league, and implementation of a Dirichlet process prior are presented.
Abstract: (2003). Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. Journal of the American Statistical Association: Vol. 98, No. 461, pp. 257-258.
4,086 citations
TL;DR: This article summarizes the revised consensus classification of lung allograft rejection and recommends the evaluation of antibody-mediated rejection, recognizing that this is a controversial entity in the lung, less well developed and understood than in other solid-organ grafts, and with no consensus reached on diagnostic features.
Abstract: In 1990, an international grading scheme for the grading of pulmonary allograft rejection was adopted by the International Society for Heart and Lung Transplantation (ISHLT) and was modified in 1995 by an expanded group of pathologists. The original and revised classifications have served the lung transplant community well, facilitating communication between transplant centers with regard to both patient management and research. In 2006, under the direction of the ISHLT, a multi-disciplinary review of the biopsy grading system was undertaken to update the scheme, address inconsistencies of use, and consider the current knowledge of antibody-mediated rejection in the lung. This article summarizes the revised consensus classification of lung allograft rejection. In brief, acute rejection is based on perivascular and interstitial mononuclear infiltrates, Grade A0 (none), Grade A1 (minimal), Grade A2 (mild), Grade A3 (moderate) and Grade A4 (severe), as previously. The revised (R) categories of small airways inflammation, lymphocytic bronchiolitis, are as follows: Grade B0 (none), Grade B1R (low grade, 1996, B1 and B2), Grade B2R (high grade, 1996, B3 and B4) and BX (ungradeable). Chronic rejection, obliterative bronchiolitis (Grade C), is described as present (C1) or absent (C0), without reference to presence of inflammatory activity. Chronic vascular rejection is unchanged as Grade D. Recommendations are made for the evaluation of antibody-mediated rejection, recognizing that this is a controversial entity in the lung, less well developed and understood than in other solid-organ grafts, and with no consensus reached on diagnostic features. Differential diagnoses of acute rejection, airway inflammation and chronic rejection are described and technical considerations revisited. This consensus revision of the working formulation was approved by the ISHLT board of directors in April 2007.
2,139 citations